^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Colorectal Cancer
    Drug:Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    08/26/2013
    Excerpt:
    Stivarga is indicated as monotherapy for the treatment of adult patients with...metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies - these include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy...
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    09/27/2012
    Excerpt:
    STIVARGA is a kinase inhibitor indicated for the treatment of patients with...Metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an antiVEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Published date:
    10/25/2022
    Excerpt:
    Regorafenib is recommended in patients pre-treated with fluoropyrimidines, oxaliplatin, irinotecan and biologics, if available, or in earlier lines of therapy following oxaliplatin and irinotecan regimen failure, depending on local approvals...
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    ...the panel added regorafenib as an additional line of therapy for patients with mCRC refractory to chemotherapy.